Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 11/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479581 | 1.00 | TAS2R14 (0.57) | TAS2R14MEN1KMT2ARORCOPRM1 | |
| SCHEMBL1965678 | 0.91 | TAS2R14 (0.49) | TAS2R14MEN1KMT2ARORCOPRM1 | |
| SCHEMBL5166106 | 0.84 | MEN1 (0.53) | TAS2R14MEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL30093246 | 0.84 | OPRM1 (0.57) | RORCOPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL8313789 | 0.81 | OPRM1 (0.51) | RORCOPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL5519308 | 0.81 | KDM4E (0.54) | RORCOPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL8313794 | 0.81 | OPRM1 (0.51) | RORCOPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL5519302 | 0.81 | KDM4E (0.54) | RORCOPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL26626553 | 0.81 | OPRM1 (0.51) | RORCOPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL5517631 | 0.81 | RORC (0.47) | TAS2R14MEN1KMT2ARORCOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| EP-1765791-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006014482-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCZ, PRKCQ, PRKCH | TAS2R14 2994/4885MEN1 4217/4885KMT2A 2429/4885 |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCH | TAS2R14 2994/4885MEN1 4217/4885KMT2A 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.